Entries by Trethera

Trethera Announces U.S. Patent Application Filed for TRE-515, Extending Major Markets Exclusivity until 2041

Los Angeles, November 2, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases is pleased to announce that it has filed a provisional patent application with the US Patent & Trademark Office for the company’s first-in-class drug TRE-515.  If granted, […]